Kisunla | search
Click here to view Kisunla news from 60+ newspapers.
Bookmark or Share- FDA approves treatment for adults with Alzheimer’s diseaseThe U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild...
- Medication for Early Symptomatic AD | Kisunla™ (donanemab-azbt) injectionGet to know Kisunla: an FDA-approved treatment for early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease. Sign up today.
- FDA Approves Kisunla (Donanemab) | Alzheimer's AssociationCHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
- Kisunla: Uses, Side Effects, Dosage, Warnings - Drugs.comKisunla is an amyloid plaque-targeting therapy that works by helping the body remove amyloid plaques in the brain, which slows the progression of Alzheimer’s disease.
- Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment ...Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of treatment with Kisunla in 12 months.
More
